Sierra Oncology
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Sierra Oncology generated cash of -$78,964,000, which is less than the previous year. Cash used in financing activities reached the amount of $79,808,000 last year. Net change in cash is therefore $694,000.
Cash Flow
| 2013 | -3.57M | -2K | 4.68M |
|---|---|---|---|
| 2014 | -21.78M | -10.28M | 58.79M |
| 2015 | -28.26M | 9.44M | 139.87M |
| 2016 | -41.16M | -146K | 196K |
| 2017 | -36.16M | -80K | 27.58M |
| 2018 | -45.11M | -118K | 51.13M |
| 2019 | -51.18M | -39K | 92.73M |
| 2020 | -52.36M | -12K | 8.90M |
| 2021 | -78.96M | -72K | 79.80M |
SRRA Cash Flow Statement (2013 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 104.35M | 147.82M | 106.34M | 100.53M | 109.00M | 150.18M | 29.15M | 2.42M | 1.31M |
Operating activities | |||||||||
Net income | -94.65M | -80.90M | -88.27M | -53.33M | -42.01M | -47.86M | -53.26M | -23.87M | -6.83M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 305K | 238K | 83K | 111K | 258K | 197K | 111K | 12K | 1K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22K |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -109K | 1.19M | -277K | -48K | -1.21M | 2.24M | 6K | 186K | -89K |
Cash generated by operating activities | -78.96M | -52.36M | -51.18M | -45.11M | -36.16M | -41.16M | -28.26M | -21.78M | -3.57M |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | -21K | -10.02M | 0 |
Investments In Property Plant And Equipment | -72K | -12K | -39K | -118K | -93K | -214K | -414K | -187K | -2K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -72K | -12K | -39K | -118K | -80K | -146K | 9.44M | -10.28M | -2K |
Financing activities | |||||||||
Common Stock Issued | 78.15M | 8.90M | 97.73M | 45.99M | 27.42M | 0 | 147.27M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 79.80M | 8.90M | 92.73M | 51.13M | 27.58M | 196K | 139.87M | 58.79M | 4.68M |
Net Change In Cash | 694K | -43.47M | 41.48M | 5.81M | -8.65M | -41.17M | 121.02M | 26.72M | 1.11M |
Cash at end of period | 105.04M | 104.35M | 147.82M | 106.34M | 100.34M | 109.00M | 150.18M | 29.15M | 2.42M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |